The world is falling behind in the race for global vaccine access

Less than a year since the COVID-19 pandemic started, AstraZeneca, Pfizer/BioNTech, and Moderna have created safe and effective vaccines against the virus, and some nations have begun vaccinating their citizens. Although this is great news and a major scientific achievement, the work isn’t done, and we’re seeing some signs that this accomplishment could be undermined by a failure to get the vaccine everywhere.

The pandemic won’t end with just a vaccine, but when there is global access to it and the people who need it the most get it first, regardless of where they live. Fair global distribution of the vaccines will save lives, help economies recover, and end the pandemic faster for everyone.

Our Vaccine Access Test measures whether countries’ and companies’ actions are bringing us closer to, or further from, global access to COVID-19 vaccines. Since our last update in November 2020, there have been some concerning trends, and a lot of changes to the scores. Here are the latest findings as of January 2021.

The latest findings

Having safe and effective vaccines within a year of the first reported COVID-19 cases is a major and historic scientific achievement, as we now have the tools to beat the virus and end the pandemic. It has shifted the discussion from “if” to “when” we could see an end to the pandemic.

Unfortunately, our Test is showing three trends that could prolong the pandemic by years:

  1. With increasing vaccine deliveries in rich countries, there is a risk for an overreliance on “trickle down” donations as a means of expanding global access.
  2. The increase in competition between rich countries is monopolizing the global supply, which could price multilaterals and poorer countries out of the picture.
  3. Supply remains the biggest barrier to global access.

The quickest way to put an end to the COVID-19 pandemic is to protect people everywhere, starting with healthcare professionals and key workers who put their own lives at risk to protect ours and the most vulnerable.

According to a study from Northeastern University’s MOBS Lab, if rich countries continue to monopolize the first 2 billion doses of the vaccine, there could be twice as many COVID-19 deaths than if the vaccine is distributed equitably. And economically, if only the countries that are currently actively developing a vaccine are able to vaccinate their populations, it could cost the global economy up to $1.2 trillion a year in GDP, according to RAND. Additionally, if low-income countries alone cannot access a COVID-19 vaccine, the world could still lose approximately $153 billion a year in GDP.

The bottom line is that hoarding vaccines in wealthy countries will ultimately slow down the pandemic recovery everywhere for everyone. Ensuring equal vaccine access isn’t only the right thing to do, it’s the smart thing to do.

How scores have changed this month

The following scores have changed as of January 2021:

  • AstraZeneca, BioNTech, CureVac, Turkey, Mexico, Pfizer, and Moderna saw small adjustments to their scores due to updates to previously released deals and new deals.
  • South Africa moved up to the top spot on the Vaccine Access Test, thanks to its first bilateral deal with AstraZeneca.
  • GSK’s score increased by 1 point.
  • Ireland is a newcomer to the test and has entered with a score of 4 out of 9.
  • The European Commission went from being in second place to sixth place.
  • Canada’s score increased by 2 points.
  • Novavax gained an additional point.
  • The United States’ score increased by 1 point.
  • Australia’s score gained a point.
  • Four new deals have been scored since the last update: Pfizer and Mexico, AstraZeneca and South Africa, Novavax and Australia, and Moderna and Korea.

Here’s a look at the latest scores

What happens next

With the current and ever-changing findings, the update for February is going to look different. To better reflect the current context in the race to develop and deploy a COVID-19 vaccine, ONE’s policy team is working to update elements of the Test’s methodology.

Learn more about our Vaccine Acces Test and the latest findings.

Sign up to Aftershocks

Sign up to our weekly Aftershocks newsletter to get the latest information on COVID-19’s impact on African countries.

By signing you agree to ONE's privacy policy, including to the transfer of your information to's servers in the United States.

You agree to receive occasional updates about ONE's campaigns. You can unsubscribe at any time.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply

Sign the petition

Demand a Global Response to Coronavirus

Demand a Global Response to Coronavirus

People all over the world are standing in solidarity with each other to fight coronavirus, but the virus keeps moving fast.

The pandemic will inevitably wreak its worst on the communities and countries that are least able to withstand the shock. Let’s stand with the most vulnerable whether they live across the street or across the ocean.

We are one world and it’s time to fight for humanity against the virus. Sign our petition telling governments that a global pandemic demands a global response.

Dear World Leaders,

The world needs a Pandemic Response Plan to:

  • Protect the vulnerable, support essential workers, and make a vaccine available to everyone
  • Support people worst hit economically
  • Strengthen health systems so we’re ready if this happens again

Sign the petition

By signing you agree to ONE’s privacy policy, including to the transfer of your information to ONE’s servers in the United States.

Do you want to stay informed about how you can help fight against extreme poverty?

Sign up to receive emails from ONE and join millions of people around the world taking action to end extreme poverty and preventable disease. We’ll only ever ask for your voice, not your money. You can unsubscribe at any time.
Privacy options
Are you sure? If you select 'Yes' we can let you know how you can make a difference. You can unsubscribe at any time.

By signing you agree to ONE's privacy policy, including to the transfer of your information to's servers in the United States.

You agree to receive occasional updates about ONE's campaigns. You can unsubscribe at any time.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply

Related Articles